Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Ann Surg Oncol. 2024 Jul;31(7):4470-4476. doi: 10.1245/s10434-024-15387-6. Epub 2024 May 11.
With new investigations and clinical trials in breast oncology reported every year, it is critical that surgeons be aware of advances and insights into the evolving care paradigms and treatments available to their patients. This article highlights five publications found to be particularly impactful this past year. These articles report on efforts to select the minimal effective dose of tamoxifen for prevention, to challenge the existing age-based screening guidelines as they relate to race and ethnicity, to refine axillary management treatment standards, to optimize systemic therapy in multidisciplinary care settings, and to reduce the burden of breast cancer-related lymphedema after treatment. Taken together, these efforts have an impact on all facets of the continuum of care from prevention and screening through treatment and survivorship.
每年都有新的乳腺癌肿瘤学研究和临床试验报告,因此外科医生了解不断发展的护理模式的进展和见解以及为患者提供的治疗方法至关重要。本文重点介绍了过去一年中发现的五篇具有特别重大影响的文章。这些文章报告了为预防而选择他莫昔芬的最小有效剂量、挑战与种族和民族有关的现有基于年龄的筛查指南、完善腋窝管理治疗标准、优化多学科护理环境中的系统治疗以及减少治疗后乳腺癌相关淋巴水肿的负担等方面的努力。这些努力共同影响着从预防和筛查到治疗和生存的护理连续体的各个方面。